A New Immune‑Engaging ADC Platform: STEAP1‑Targeted Vandortuzumab–Exatecan

Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses.

A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the prostate 1 (STEAP1). STEAP1 is a prostate‑lineage–restricted, androgen‑receptor–regulated surface antigen highly overexpressed in castration‑resistant disease, making it an attractive target for antibody‑based therapies. Earlier work with an anti‑STEAP1 ADC (DSTP3086S) already showed activity in metastatic castration‑resistant prostate cancer, validating STEAP1 as a productive entry point for cytotoxic payloads.

What is new in this work is the explicit effort to design the ADC as an immune‑engaging agent rather than a simple cytotoxic delivery system. The group tested multiple linker‑payload combinations on the vandortuzumab backbone and assessed Fcγ receptor engagement, antigen presentation, and T‑cell activation in vitro. They found that STEAP1‑specific Fcγ receptor engagement is required for optimal antigen cross‑presentation and downstream T‑cell stimulation, meaning the ADC does more than just kill tumor cells, it helps prime an adaptive immune response.

Among the payloads evaluated, exatecan‑based constructs stood out for their particularly strong immunostimulatory activity. Exatecan is a topoisomerase I inhibitor delivered via a cleavable, membrane‑permeable linker system, similar in concept to deruxtecan‑type ADCs. In bone‑metastatic and syngeneic immunocompetent APMR models, the vandortuzumab‑exatecan conjugate mediated durable tumor control and, crucially, induced adaptive immune memory that protected animals from tumor rechallenge. This suggests the construct can convert a largely immune‑silent environment into one capable of sustaining T‑cell–mediated surveillance.

The concept is clear: immune activation should be treated as a design parameter, not an afterthought, when engineering ADCs for prostate cancer. By systematically comparing linker‑payload platforms and measuring immune readouts, the researchers that payload choice can significantly shape immunostimulation. Exatecan emerged as the most immunostimulatory option in their system, but the platform approach allows for tailoring to different clinical contexts.

For patients with androgen pathway modulation‑resistant (APMR) prostate cancer (aka castration-resistant prostate cancer CRPC), this work implies that STEAP1‑targeted ADCs can be positioned not only as cytotoxic agents but also as immune‑engaging therapies capable of generating durable, T‑cell–driven responses.

Source.